<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Appili Therapeutics Inc — News on 6ix</title>
    <link>https://6ix.com/company/appili-therapeutics-inc</link>
    <description>Latest news and press releases for Appili Therapeutics Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 30 Mar 2026 11:19:36 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/appili-therapeutics-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835f75678dffbe2df130047.webp</url>
      <title>Appili Therapeutics Inc</title>
      <link>https://6ix.com/company/appili-therapeutics-inc</link>
    </image>
    <item>
      <title>Appili Therapeutics to Exhibit at World Vaccine Congress Washington</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-to-exhibit-at-world-vaccine-congress-washington</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-to-exhibit-at-world-vaccine-congress-washington</guid>
      <pubDate>Mon, 30 Mar 2026 11:19:36 GMT</pubDate>
      <description>Appili Presentation Highlights Recent Collaborations and Funding Milestones     Appili Executives...</description>
    </item>
    <item>
      <title>Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-announces-closing-second-121900342</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-announces-closing-second-121900342</guid>
      <pubDate>Wed, 18 Feb 2026 12:19:00 GMT</pubDate>
      <description>NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, is pleased to announce that it has closed the second tranche of its previously announced non-brokered private placement for aggregate gross proceeds of C$100,000 (the “</description>
    </item>
    <item>
      <title>Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-reports-financial-operational-231500556</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-reports-financial-operational-231500556</guid>
      <pubDate>Thu, 12 Feb 2026 23:15:00 GMT</pubDate>
      <description>US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase 1 LIKMEZ® (ATI-1501) Commercial Momentum with Increased U.S. Market Adoption HALIFAX, Nova Scotia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its fi</description>
    </item>
    <item>
      <title>Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-announces-closing-of-first-tranche-of-non-brokered-private-placement</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-announces-closing-of-first-tranche-of-non-brokered-private-placement</guid>
      <pubDate>Thu, 18 Dec 2025 12:31:16 GMT</pubDate>
      <description>NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES    HALIFAX, ...</description>
    </item>
    <item>
      <title>The Lundquist Institute and its start-up company Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/the-lundquist-institute-and-its-start-up-company-vitalex-biosciences-announces-strategic-advancement-of-second-generation-fungal-vaccine-vxv-01-through-phase-1-trials-under-dollar40-million-competitive-contract-from-nihniaid</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/the-lundquist-institute-and-its-start-up-company-vitalex-biosciences-announces-strategic-advancement-of-second-generation-fungal-vaccine-vxv-01-through-phase-1-trials-under-dollar40-million-competitive-contract-from-nihniaid</guid>
      <pubDate>Mon, 15 Dec 2025 15:30:00 GMT</pubDate>
      <description>Los Angeles, CA, Dec. 15, 2025 (GLOBE NEWSWIRE) --   The Lundquist Institute   (TLI) and its star...</description>
    </item>
    <item>
      <title>Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2026</guid>
      <pubDate>Thu, 13 Nov 2025 22:21:13 GMT</pubDate>
      <description>New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposa...</description>
    </item>
    <item>
      <title>The Lundquist Institute and Its Start-Up Company Vitalex Biosciences Announce Strategic Advancement of Second-Generation Fungal Vaccine VXV-01 Through Phase 1 Trials Under $40 Million Competitive Contract From NIH/NIAID</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/the-lundquist-institute-and-its-start-up-company-vitalex-biosciences-announce-strategic-advancement-of-second-generation-fungal-vaccine-vxv-01-through-phase-1-trials-under-dollar40-million-competitive-contract-from-nihniaid</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/the-lundquist-institute-and-its-start-up-company-vitalex-biosciences-announce-strategic-advancement-of-second-generation-fungal-vaccine-vxv-01-through-phase-1-trials-under-dollar40-million-competitive-contract-from-nihniaid</guid>
      <pubDate>Wed, 12 Nov 2025 20:54:23 GMT</pubDate>
      <description>Los Angeles, California, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Lundquist Institute (TLI) and its ...</description>
    </item>
    <item>
      <title>Appili Therapeutics Announces Proposed Non-Brokered Private Placement</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-announces-proposed-non-brokered-private-placement</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-announces-proposed-non-brokered-private-placement</guid>
      <pubDate>Wed, 05 Nov 2025 12:16:21 GMT</pubDate>
      <description>NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES       HALIFA...</description>
    </item>
    <item>
      <title>Appili Therapeutics to Attend BARDA Innovation Symposium 2025</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-to-attend-barda-innovation-symposium-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-to-attend-barda-innovation-symposium-2025</guid>
      <pubDate>Wed, 22 Oct 2025 11:20:48 GMT</pubDate>
      <description>HALIFAX, Nova Scotia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTC ...</description>
    </item>
    <item>
      <title>Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-and-its-partner-vitalex-biosciences-awarded-contract-from-niaid-valued-at-up-to-usdollar40-million-to-develop-fungal-vaccine-vxv-01</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-and-its-partner-vitalex-biosciences-awarded-contract-from-niaid-valued-at-up-to-usdollar40-million-to-develop-fungal-vaccine-vxv-01</guid>
      <pubDate>Wed, 01 Oct 2025 11:17:39 GMT</pubDate>
      <description>Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional opti...</description>
    </item>
    <item>
      <title>Appili Therapeutics Announces Results of&amp;#xA0;Annual and Special Meeting of Shareholders</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-announces-results-ofandxa0annual-and-special-meeting-of-shareholders</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-announces-results-ofandxa0annual-and-special-meeting-of-shareholders</guid>
      <pubDate>Tue, 23 Sep 2025 21:01:18 GMT</pubDate>
      <description>HALIFAX, Nova Scotia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTC...</description>
    </item>
    <item>
      <title>Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-announces-results-annual-210100623</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-announces-results-annual-210100623</guid>
      <pubDate>Tue, 23 Sep 2025 21:01:00 GMT</pubDate>
      <description>HALIFAX, Nova Scotia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders held earlier today (the “Meeting”). Based on the proxies received and the vote conducted at the Meeting, all tabled resolutions were approved by the shareholders of the Company (the “Sh</description>
    </item>
    <item>
      <title>Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-to-present-progress-on-tularemia-biodefense-vaccine-at-nato-cbrn-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-to-present-progress-on-tularemia-biodefense-vaccine-at-nato-cbrn-conference</guid>
      <pubDate>Tue, 09 Sep 2025 11:20:44 GMT</pubDate>
      <description>HALIFAX, Nova Scotia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTC...</description>
    </item>
    <item>
      <title>Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-reports-financial-and-operational-results-for-first-quarter-of-fiscal-year-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-reports-financial-and-operational-results-for-first-quarter-of-fiscal-year-2026</guid>
      <pubDate>Thu, 14 Aug 2025 21:05:53 GMT</pubDate>
      <description>Submitted two additional U.S. government funding proposals during the quarter, bringing the total...</description>
    </item>
    <item>
      <title>Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-and-colleagues-publish-manuscript-demonstrating-efficacy-of-ati-1701-tularemia-vaccine</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-and-colleagues-publish-manuscript-demonstrating-efficacy-of-ati-1701-tularemia-vaccine</guid>
      <pubDate>Wed, 06 Aug 2025 11:21:23 GMT</pubDate>
      <description>Peer-reviewed publication highlights ATI-1701&amp;#x2019;s robust protection against aerosolized Fran...</description>
    </item>
    <item>
      <title>Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-reports-fiscal-year-2025-financial-and-operational-results</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-reports-fiscal-year-2025-financial-and-operational-results</guid>
      <pubDate>Wed, 25 Jun 2025 22:04:38 GMT</pubDate>
      <description>LIKMEZ&amp;#x2122; (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial ...</description>
    </item>
    <item>
      <title>Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-announces-formal-termination-of-arrangement-agreement-with-aditxt-inc</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-announces-formal-termination-of-arrangement-agreement-with-aditxt-inc</guid>
      <pubDate>Fri, 30 May 2025 11:17:00 GMT</pubDate>
      <description>NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...</description>
    </item>
    <item>
      <title>Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-provides-update-on-arrangement-with-aditxt-inc</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-provides-update-on-arrangement-with-aditxt-inc</guid>
      <pubDate>Mon, 19 May 2025 12:00:40 GMT</pubDate>
      <description>NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...</description>
    </item>
    <item>
      <title>Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-and-colleagues-publish-manuscript-on-the-prevention-and-emergency-response-to-tularemia</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-and-colleagues-publish-manuscript-on-the-prevention-and-emergency-response-to-tularemia</guid>
      <pubDate>Thu, 01 May 2025 11:34:07 GMT</pubDate>
      <description>HALIFAX, Nova Scotia, May 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPin...</description>
    </item>
    <item>
      <title>Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ&amp;#xAE;(TM)</title>
      <link>https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-announces-new-patents-granted-for-commercial-stage-asset-likmezandxaetm</link>
      <guid isPermaLink="true">https://6ix.com/company/appili-therapeutics-inc/news/appili-therapeutics-announces-new-patents-granted-for-commercial-stage-asset-likmezandxaetm</guid>
      <pubDate>Mon, 28 Apr 2025 11:41:34 GMT</pubDate>
      <description>New patents provide additional composition of matter and methods of use claims, strengthening the...</description>
    </item>
  </channel>
</rss>